16th week of 2009 patent applcation highlights part 34 |
Patent application number | Title | Published |
20090098024 | DISPENSING MECHANISM, DISPENSING APPARATUS AND DISPENSING METHOD FOR LIQUID TO BE DISPENSED - There is provided a dispensing mechanism for a liquid to be dispensed that does not damage microspherical bodies such as an erythrocyte and a liposome in the liquid to be dispensed when the liquid to be dispensed such as a sample and test liquid is sucked/discharged with a pipette. | 2009-04-16 |
20090098025 | REACTION CONTAINER KIT - A reaction container kit in which a judgment can be made easily whether a sample is not yet injected or injected already while a sample is prevented from being injected into an incorrect reaction container erroneously. Before a sample is injected, the bar code ( | 2009-04-16 |
20090098026 | Ceiling fan mounted air freshener device - The present invention is directed toward an air freshener that is constructed and arranged to be secured to the supporting shaft of a ceiling fan. One embodiment of the device includes a scented ring of wickable material having an inner aperture and split through one side. The aperture is sized to cooperate with the supporting shaft of the fan and the split allows the scented ring to be sprung apart for easy installation of the device about the supporting rod. The wickable material includes properties that allow the device to remain in position about the supporting rod once installed while wicking a fragrance composition substantially to its surface for distributing a fragrance evenly throughout an open area, such as a large room. The inner and bottom surfaces of the scented ring may include a polymeric coating to prevent the fragrance composition from wicking to a supporting surface. | 2009-04-16 |
20090098027 | MICROREACTOR DEVICE - A microreactor device comprises: a microchannel that sends one or more fluids; and a section that isolates vibrations to a first portion of the microchannel. | 2009-04-16 |
20090098028 | System for stabilizing gas hydrates at low pressures - The present invention provides a system for stabilizing gas and particularly gas hydrates at low pressures and for safe storage and transportation of the gas. The invention also provides minimization of the decomposition of the gas in hydrate form. | 2009-04-16 |
20090098029 | METHOD OF FORMING A SEALED CHANNEL OF A MICROFLUIDIC REACTOR AND A MICROFLUIDIC REACTOR COMPRISING SUCH CHANNEL - In a method according to the invention for forming a sealed channel ( | 2009-04-16 |
20090098030 | MICROREACTOR AND METHOD FOR MANUFACTURING SAME AND METHOD FOR MANUFACTURING A SUBSTRATE FOR A MICROREACTOR - The invention relates to a microreactor having a substrate ( | 2009-04-16 |
20090098031 | Method and apparatus for sanitizing shoe soles - A shoe sole sanitizing device is made up of a tray having a reservoir containing a sanitizing solution, a perforated grate with scraping edges on the tray being of a resiliency sufficient to be depressed beneath the upper surface of said solution when stepped on by a wearer, and a drain for removal of used solution and particles which collect in the reservoir. In one version, the fill and drain system may be mounted within the tray, or mounted on the tray in a portable version that may be easily moved from place to place, or in another version may have greater capacity for high volume use. | 2009-04-16 |
20090098032 | METHODS OF MAKING ALUMINOSILICATE COATED ALUMINA - An aluminosilicate coated alumina structure that is substantially free of alkaline metal impurities contains an aluminosilicate coating at least partially surrounding an alumina core. The aluminosilicate coated alumina structure is useful as a catalyst or catalyst support. | 2009-04-16 |
20090098033 | Carbon-Encased Metal Nanoparticles and Sponges, Methods of Synthesis, and Methods of Use - We disclose novel metallic nanoparticles coated with a thin protective carbon shell, and three-dimensional nano-metallic sponges; methods of preparation of the nanoparticles; and uses for these novel materials, including wood preservation, strengthening of polymer and fiber/polymer building materials, and catalysis. | 2009-04-16 |
20090098034 | Method of treating atmospheric pollutants - A method of reducing at least one atmospheric oxidising pollutant, such as ozone, with a reducing agent comprises contacting the reducing agent with the at least one atmospheric oxidising pollutant, wherein the reducing agent comprises a precious metal-free trap material, such as a zeolite, including at least one trapped atmospheric reducing pollutant, e.g. a hydrocarbon, whereby as the at least one atmospheric oxidising pollutant is reduced the at least one trapped atmospheric reducing pollutant is oxidised. | 2009-04-16 |
20090098035 | CO2 CAPTURE METHOD WITH THERMAL INTERGRATION OF REGENERATOR | 2009-04-16 |
20090098036 | ADSORPTION COMPOSITION AND METHOD OF REMOVING CO FROM STREAMS - Carbon monoxide is removed from streams by adsorption on an adsorption composition which comprises copper, zinc and zirconium oxides and whose copper-comprising component has a degree of reduction, expressed as weight ratio of metallic copper to the sum of metallic copper and copper oxides, calculated as CuO, of at least 90% and not more than 97%. | 2009-04-16 |
20090098037 | ADSORPTION COMPOSITION AND METHOD OF REMOVING CO FROM STREAMS - Carbon monoxide is removed from streams by adsorption on an adsorption composition which comprises copper, zinc and zirconium oxides and whose copper-comprising component has a degree of reduction, expressed as weight ratio of metallic copper to the sum of metallic copper and copper oxides, calculated as CuO, of at least 45% and not more than 75%. | 2009-04-16 |
20090098038 | SINTERED BODY OF TITANIUM COMPOUND - The present invention provides a sintered body of titanium compound obtained by sintering the titanium compound and a method for producing the same. A titanium compound represented by the formula (1) or (2) below is sintered. | 2009-04-16 |
20090098039 | Silicon Production Method - There is provided a silicon production method which comprises producing semiconductor grade silicon while producing solar grade silicon by converting a portion of trichlorosilane into silicon for solar cells. | 2009-04-16 |
20090098040 | FLUORINE STORAGE MATERIAL - There is provided a fluorine storage material comprising a novel fluorinated carbon nanohorn, which stores a large amount of fluorine per its unit mass, withstand repeated use for fluorine storage, and enables a high purity fluorine gas to be taken out by a safe and efficient method, and also there is provided a method of taking out a fluorine gas by applying heat to the fluorine storage material or placing the fluorine storage material in a pressure-reduced atmosphere. | 2009-04-16 |
20090098041 | Multistage Method for Manufacturing Titanium Dioxide - The manufacture of titanium dioxide by oxidation of titanium tetrachloride in a multistage method, where both oxygen and titanium tetrachloride are added in several stages. In the first stage gaseous TiCl | 2009-04-16 |
20090098042 | Method for Manufacturing Titanium Dioxide - The manufacture of titanium dioxide by oxidation of titanium tetrachloride in a plug flow reactor, wherein the titanium tetrachloride is introduced into the reactor in at least two stages and is used exclusively in liquid form. The total quantity of liquid TiCl | 2009-04-16 |
20090098043 | METHOD FOR PREPARING ZINC OXIDE NANOSTRUCTURES AND ZINC OXIDE NANOSTRUCTURES PREPARED BY THE SAME - Example embodiments provide a method for preparing zinc oxide nanostructures. According to the method, zinc oxide nanostructures are prepared by dipping a substrate having a zinc (Zn) seed layer thereon in an aqueous solution of hexamethyleneamine and dropwise adding an aqueous solution of zinc nitrate to the aqueous solution of hexamethyleneamine. In addition, zinc ions can be continuously supplied in a constant amount as the reactions of the reactants proceed to prepare high-quality zinc oxide nanostructures at a high growth rate. Furthermore, zinc oxide nanostructures can be prepared on a large-area substrate at a low processing temperature regardless of the substrate material. Example embodiments also provide zinc oxide nanostructures prepared by the method. | 2009-04-16 |
20090098044 | SOLID PARTICLES FROM CONTROLLED DESTABILISATION OF MICROEMULSIONS - The present invention relates to a process for making a particulate substance. The process comprises providing an emulsion, optionally a microemulsion, comprising droplets dispersed in a continuous liquid phase. At least some of the droplets of the emulsion comprise nuclei. The droplets are then at least partially destabilised to form the particulate substance. | 2009-04-16 |
20090098045 | Cytotoxicity mediation of cells evidencing surface expression of MCSP - This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention. | 2009-04-16 |
20090098046 | Combination Cancer Therapy with Anti-PSMA Antibodies - This invention includes compositions and methods for combination cancer treatments, particularly involving at least one cytotoxic agent used in combination with an anti-PSMA monoclonal antibody. | 2009-04-16 |
20090098047 | BIOCONJUGATES OF METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS - The present invention is directed to bioconjugates of complexes represented by the formula: | 2009-04-16 |
20090098048 | RADIOACTIVE TYROSINE DERIVATIVE, METHOD FOR PRODUCING SAME, LABELING AGENT FOR POSITRON IMAGING AND MEDICAL AGENT FOR ASSESSING GRADE OF MALIGNANCY OF TUMOR RESPECTIVELY COMPOSED OF RADIOACTIVE TYROSINE DERIVATIVE, AND METHOD FOR DETECTING TUMOR -
It is intended to provide a radioactive tyrosine derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof:
| 2009-04-16 |
20090098049 | Targeting transducible molecules to specific cell types - The disclosure provides fusion polypeptides and constructs useful in targeting molecules including diagnostics and therapeutics to a cell type of interest. The fusion constructs include a protein transduction domain, a ligand domain and a cargo domain. Also provided are methods of treating disease and disorders such as cell proliferative disorders. | 2009-04-16 |
20090098050 | CALCIUM BINDING PEPTIDES - Disclosed herein are a class of compounds comprising peptides of the sequence (X-Y-Z) | 2009-04-16 |
20090098051 | BACILLUS THURINGIENSIS TOXIN - A new Bt Cry toxin, Cry1M is able to exert insecticidal effects on insects and/or nematodes in general, and in addition, on insects that have acquired resistance to alternative Cry proteins. | 2009-04-16 |
20090098052 | TRANSGENIC MICE - A transgenic non-human animal, in particular a transgenic mouse encoding Aβ peptide proteins, which have been implicated in Aβ peptide-related diseases. Cells and cell lines comprising transgenes encoding for Aβ peptide. Methods and compositions for evaluating agents that affect Aβ peptide, for use in compositions for the treatment of Aβ peptide-related diseases. | 2009-04-16 |
20090098053 | LA1 - THE GENOME OF A LACTOBACILLUS STRAIN - The present invention pertains to the use of the DNA sequence of a | 2009-04-16 |
20090098054 | METHODS AND COMPOSITIONS RELATING TO PROMOTER REGULATION BY MUC1 AND KLF PROTEINS - This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or inflammatory cell growth and/or activation. The invention provides methods of, and compositions useful for, inhibiting interactions between MUC1 and a kruppel-like factor (KLF), method of inhibiting interactions between a KLF protein and the p53 promoter, methods of inhibiting the interaction between MUC1 and the p53 promoter, methods of increasing p53 activity, and methods of increasing histone acetylation. The invention also provides screening methods for identifying compounds that inhibit the aforementioned interactions. Pharmaceutical compositions containing the identified compounds can be useful in treating cancers and inflammatory conditions. | 2009-04-16 |
20090098055 | Methods and Compositions for Diagnosing Disease - The present invention relates to methods and compositions for diagnosing a disease or disorder in a subject by introducing into cells of the subject a diagnostic gene switch construct and monitoring expression of a reporter gene. The invention further relates to methods and compositions for monitoring the progression of a disease or disorder or the effectiveness of a treatment for a disease or disorder. | 2009-04-16 |
20090098056 | ALPK1 GENE VARIANTS IN DIAGNOSIS RISK OF GOUT - The present invention relates to a method of identifying a human subject having an elevated risk of gout and/or hyperuricemia by detecting the occurrence of at least one SNP associated with an elevated risk of gout in an ALPK1 gene in a biological sample from the subject, or by determining the expression level of an ALPK1 gene in a biological sample from the subject. Also disclosed is an isolated nucleic acid molecule, its complement or gene variant comprising at least one of the polymorphisms identified herein to be associated with gout and/or hyperuricemia, a kit for performing a diagnostic test to identify a human subject having an elevated risk of gout and/or hyperuricemia, and a method of selecting or identifying a compound useful for treating gout and/or hyperuricemia. | 2009-04-16 |
20090098057 | SILICA-CORED CARRIER PARTICLE - A nanoparticulate imaging probe with an oxide core, a biocompatible polymeric shell covalently attached to the oxide core, a dye, and a cleavable spacer that covalently binds the dye to the probe. When the spacer is cleaved, the dye is liberated from the probe. The emissions of the dye are quenched when the dye is bound to the probe and not quenched when the dye is liberated from the probe. The spacer can be, for example, a peptide. The oxide core can be, for example, a silicon oxide core. | 2009-04-16 |
20090098058 | METHOD OF INJECTING LIQUID AGENTS AT ACUPUNCTURE POINTS TO ARRIVE INTERNAL ORGANS AND METHOD OF VISUALIZING ARRIVAL OF LIQUID AGENTS - Provided are a method of injecting a visualizing material into a point in the vicinity of the Jung-Wan and a method of visualizing arrival of liquid agent in order to verify that the visualizing material injected arrives at internal organs. A point having the lowest electric resistance is found in the vicinity of Jung-Wan of the subject by using an electro acupuncture point detector. The visualizing material is injected into the point by means of an injecting instrument and then verified at least one point of the pancreas and the threadlike structures on top of the surface of the pancreas. The visualizing material is an alcian blue solution or a nanoparticle-containing solution labeled with fluorescent organic material. | 2009-04-16 |
20090098059 | CONTRAST AGENTS - The present invention relates to iodine containing compounds containing a central optionally substituted cyclohexane central moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds. | 2009-04-16 |
20090098060 | Aerosol Compositions - An aerosol composition comprising: 0.01 wt % to 1.00 wt % sodium borate; 0.01 wt % to 1.50 wt % polyglycerol ester surfactant; <30 wt % propellant; and 67.5 wt % to 85.0 wt % water. Methods of manufacture of an aerosol air freshener are also described wherein the aerosol composition further comprises a fragrance. | 2009-04-16 |
20090098061 | SOLUTION FOR TISSUE ADHESION PREVENTION AND METHOD FOR TISSUE ADHESION PREVENTION - The objective of the invention is to provide a solution for tissue adhesion prevention and a method for tissue adhesion prevention that are applicable to general surgery and in which covering condition during surgery is stable and convenient. The invention is the solution for tissue adhesion prevention of which the active ingredient is trehalose. Also, it contains at least one or more among antioxidants, chelates, antiseptics, hemostatics, anti-inflammatory agents, and polysaccharides, mucopolysaccharides, salts of polysaccharides and salts of mucopolysaccharides having lubricating properties. This solution for tissue adhesion prevention is provided as any form of perfusion fluid, spray fluid, solution for spray or vaporization administration, foam-like aerosol preparation, injection solution for intravenous fluids, intravenous fluid. | 2009-04-16 |
20090098062 | Activated Peroxide Solutions and a Process for the Preparation thereof - The present invention discloses an activated biocidal aqueous solution containing hydrogen peroxide (activated peroxide solution) obtainable by subjecting an initial solution of hydrogen peroxide in water to a non-thermal electrical discharge process, such as a glow discharge plasma or a corona discharge. The resulting activated peroxide solution containing 0.05 to 20% (w/w) hydrogen peroxide has a pH in the range of 2 to 4, an oxidation-reduction potential (ORP) in the range of 400 to 600 mV, and the solution when having a peroxide content in the range of 0.05% to 0.5% (w/w) has a conductivity in the range of 100 to 500 μSiemens/cm, the solution when having a peroxide content in the range of 0.1% to 5% (w/w) has a conductivity in the range of 100 to 450 μSiemens/cm, and the solution when having a peroxide content in the range of 5% to 20% (w/w) has a conductivity in the range of 100 to 350 μSiemens/cm. The pH, ORP and conductivity are measurable under conditions essentially without the presence of additional compounds in the solution. The biocidal activity of the solution is substantially higher than that of a common peroxide solution. The biocidal solution may be used for any purpose where disinfecting and/or sanitizing and/or cleaning and/or bleaching and/or preservative activity is required. The present invention further discloses a non-thermal electrical discharge process, in particular a pulsed corona induced low frequency pulsed DC plasma discharge process, for the preparation of the activated peroxide solution. | 2009-04-16 |
20090098063 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE - The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs in the prevention and treatment of a disease caused by a pathogen, for example, a DNA or RNA virus. | 2009-04-16 |
20090098064 | METHOD OF TREATING PULMONARY EDEMA OR PULMONARY INFLAMMATION - The invention provides a method for preventing or treating pulmonary edema and/or pulmonary inflammation in a subject by the administration of at least one nucleotidase. The subject is preferably a human subject. The nucleotidase is preferably of a mammalian origin, such as a human origin. The NTPDase and NPP families of nucleotidases are particularly useful for the present invention. The method reduces the bioavailability of in situ signaling extracellular nucleotides, thereby disturbing the pathological pathways in ventilator-induced lung injury (VILI) and respiratory syncytial virus infection (RSV) and other disorders such as chronic obstructive pulmonary disorder. Local administration such as inhalation is a preferred route of administration. | 2009-04-16 |
20090098065 | COMPOSITION AND METHODS FOR THE TREATMENT OF SKIN DISORDERS - Methods and pharmaceutical compositions for use in the treatment of benign or malignant proliferative pathologies are disclosed. The methods involve the topical administration of nicotinamide or a nicotinamide derivative in combination with a vitamin D compound. The combination is shown to act in synergy and is especially useful for treatment of psoriasis and other skin disorders. | 2009-04-16 |
20090098066 | Substituted bicyclo [2.2.2] oct/5-ene compounds and their use as cooling agents - Used as cooling agents are the compounds of 1/7-isopropyl-4/5-methyl-bicyclo[2.2.2]oct-5-ene derivatives of the formula (I) | 2009-04-16 |
20090098067 | Foamable sanitizing compositions - Foamable sanitizing compositions are disclosed. The compositions contain alcohol, water, a foaming agent, and a foam strengthening agent. The foaming agent which may comprise a derivatized dimethicone has been found to cause the alcohol solution to foam even though alcohol has various defoaming properties. The foam strengthening agent may comprise, for instance, a betaine that contains organic molecules wherein at least 90% of the organic molecules have a carbon chain length of 18 carbon atoms or greater. In one embodiment, the composition can be contained in a non-aerosol dispensing container that mixes the composition with air causing the composition to foam when dispensed. | 2009-04-16 |
20090098068 | Self-tanning cosmetic - The present invention provides a self tanning cosmetic containing 0.2-20.0 mass % of dihydroxyacetone and 0.1-10.0 mass % of an inorganic pigment powder whose surface is treated with silica coating followed by a hydrophobing treatment. | 2009-04-16 |
20090098069 | TRANSDERMAL, ALCOHOL-FREE, PHARMACEUTICAL COMPOSITIONS - An alcohol-free, transdermal drug delivery composition administered via a metered spray drug delivery device is described herein. The non-occlusive transdermal drug delivery composition includes a therapeutically effective amount of at least one physiologically active agent or prodrug thereof, an effective amount of at least one dermal penetration enhancer; and at least one non-volatile liquid. The transdermal drug delivery composition is administered to a dermal or mucosal surface of an animal needing the same using a metered spray device capable of delivering a fine spray of substantially uniform particle size to minimize the required drying time therefor. | 2009-04-16 |
20090098070 | SUNSCREEN COMPOSITIONS WITH LOW EYE-STING AND HIGH SPF - Sunscreen compositions that prevent, reduce or minimize eye-stinging while maintaining a high level of SPF protection. | 2009-04-16 |
20090098071 | Cosmetic and dermatological light protection formulations in the form of O/W macroemulsions or O/W microemulsions, with a content of dihydroxyacetone - A process for preparing a sprayable self-tanning oil-in-water microemulsion having an oil droplet diameter in a range of from about 10 | 2009-04-16 |
20090098072 | ANTIOXIDANTS - The invention relates to the use of compounds of formula (X—Ar—Y), in which X and Y respectively are selected independently of one another from the groups H, C- | 2009-04-16 |
20090098073 | Phase change visual indicating composition - A skin sealant composition of a film former and a plasticizer and having various color changing dyes may be used to indicate that the composition has dried. The dyes change color in response to the phase change, i.e., drying of the film former. The dye may be added either directly to the composition, incorporated into a sponge on an applicator through which the composition is dispensed and applied, applied separately or applied simultaneously from a separate reservoir. The amount of dye in the composition can be adjusted to provide a visual cue to the user of the application area and the extent of cure though should generally be in the range of 3000 to 10000 ppm. | 2009-04-16 |
20090098074 | Keratin-Binding Effector Molecules Containing Reactive Dyes - The invention relates to keratin-binding effector molecules comprising reactive dyes and keratin-binding polypeptides and to their use in hair-dyeing preparations. The present invention further relates to a method of dyeing hair. | 2009-04-16 |
20090098075 | HOPS-BASED DEODORANT - The present invention relates to deodorants and other body care products comprising a CO | 2009-04-16 |
20090098076 | Method For the Production of a Keratin-Binding Effector Molecule - The invention relates to a method of producing keratin-binding effector molecules, and to intermediates and end-products of the method according to the invention and to the use of the keratin-binding effector molecules produced according to the invention in dermocosmetics. In addition, the invention relates to a method of applying dermocosmetically active ingredients to skin and/or hair and to a method of increasing the residence time of an active ingredient on skin and hair. | 2009-04-16 |
20090098077 | Two-Phase Composition for Improving Curl Retention - The present invention is related to a composition for conditioning and improving curl retention of permanently shaped and/or natural curly hair comprising two optically separated phases at zero shear rate which becomes homogeneous upon shaking and returns to optically separated phases. Specifically, present invention is on two phase composition for hair comprising 5 to 50%, by weight calculated to total composition, oil phase and 50 to 95%, by weight calculated to total composition, an oil phase and 50 to 95%, by weight calculated to total composition, an aqueous phase wherein oil phase comprises at least one volatile oil at a concentration of 70 to 100%, by weight, calculated to the content of oil phase, and aqueous phase comprises 0.1 to 20% by weight calculated to the content of aqueous phase at least one fixing polymer, 10 to 40% by weight calculate to the content of aqueous phase at least one water miscible organic solvent and 0.05 to 2% by weight calculated to the content of the aqueous phase at least one cationic surfactant wherein oil and aqueous phases are optically separated at zero shear rate and becomes homogeneous upon shaking and returns again to optically separated two phases. | 2009-04-16 |
20090098078 | Water-In-Oil Microemulsions for Hair Treatment - The present invention provides a water-in-oil microemulsion for hair treatment comprising: (a) an oil phase comprising: (i) a first oily component which is one or more glyceride fatty esters, and (ii) a second oily component which is one or more hydrocarbon oils of average carbon chain length less than 20 carbon atoms, and (b) a hydrophilic phase comprising: (i) water, (ii) a nonionic emulsifier which is an ethoxylated alcohol having an HLB of at least 6, and (iii) a hair conditioning agent. | 2009-04-16 |
20090098079 | PRODUCT RELEASE SYSTEM FOR ATOMIZING COSMETIC HAIR COMPOSITIONS CONTAINING CATIONIC POLYMERS - A product release system for atomizing cosmetic hair compositions is described, which has (a) pressure-resistant packaging, (b) a capillary-containing spray head, and (c) a propellant-containing cosmetic composition, which contains at least one film-forming, hair-setting, or hair-conditioning cationic polymer. The atomization is done using the capillary. The capillary preferably has a diameter of 0.1 to 1 mm and a length of 5 to 100 mm. The spray rate is preferably 0.01 to 5 g/s. The composition can particularly be a gel, wax, or emulsion. | 2009-04-16 |
20090098080 | METHOD OF CONTROLLING OIL-ABSORBING PROPERTIES OF A SILICONE RUBBER POWDER - A method of controlling oil-absorbing properties of a silicone rubber powder characterized by keeping a silicone rubber powder in hot storage at a temperature in the range of 40° C. to 150° C. or in cold storage at a temperature in the range of 0° C. to 10° C. | 2009-04-16 |
20090098081 | System for providing a method for applying a skin sealant having a phase change visual indicating component - A system for providing a method of sealing skin with a film forming polymer is provided. The system includes providing an at least two part applicator containing a sealant composition in one or more frangible containers, providing instructions for using the applicator associated therewith, where the method including moving at least one of said applicator parts from a first position to a second position and applying said sealant to skin. The composition has film former, a plasticizer and 3000 to 10000 ppm of a dye that changes color when is undergoes a phase change. The color change is visible to a human eye under normal light conditions. changing dyes may be used to indicate that the composition has dried. The dyes change color in response to the phase change, i.e., drying of the film former. The dye may be added either directly to the composition, incorporated into a sponge on an applicator through which the composition is dispensed and applied, applied separately or applied simultaneously from a separate reservoir. The amount of dye in the composition can be adjusted to provide a visual cue to the user of the application area and the extent of cure though should generally be in the range of 3000 to 10000 ppm. | 2009-04-16 |
20090098082 | substiuted organopolysiloxanes and use thereof - The invention relates to new compounds of Formula | 2009-04-16 |
20090098083 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS - The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments. | 2009-04-16 |
20090098084 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects. | 2009-04-16 |
20090098085 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters or prodrugs thereof: | 2009-04-16 |
20090098086 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS - The invention relates to thienopyrimidine and pyrazolopyrimidine compounds of the Formulas (Ia) and (IIa), | 2009-04-16 |
20090098087 | METHOD OF TREATING LACTOSE INTOLERANCE USING GENETICALLY ENGINEERED BACTERIA - The present invention relates to genetically engineered bacteria that are able to colonize the mammalian intestine and actively produce mammalian lactase (lactose-phlorizin hydrolase or LPH). This lactose-digesting enzyme is stable and active under the conditions normally found in the mammalian small intestine. Experimental subjects colonized with the genetically engineered bacteria show improved ability to digest lactose in dairy foods. | 2009-04-16 |
20090098088 | Methods And Kits For The Treatment Of Diverticular Conditions - The present invention relates to methods and kits that are useful for the treatment of diverticular disease, diverticulitis, and combinations thereof. The methods comprise administering to a mammal in need of treatment a composition comprising a probiotic, either alone or in combination with an anti-inflammatory or an antibiotic. | 2009-04-16 |
20090098089 | REOVIRUS FOR THE TREATMENT OF NEOPLASIA - Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated. | 2009-04-16 |
20090098090 | VITRO IMMUNIZATION - The present invention relates generally to a method of generating lymphocytes specific for particular antigens. More particularly, the present invention provides a method for generating antigen-reactive T- cells and even more particularly cytotoxic (CD8+) T-cells in 10 vitro specific for antigens such as peptide antigens. The method of the present invention enables in vitro T-cell priming for particular antigens such as antigens on cancer cells, pathogenic cells, viruses or cells infected with viruses. The present invention is useful in identifying particularly immunogenic antigens for immunotherapy. Furthermore, as a consequence, the present invention is useful in avoiding the need for expensive and time 15 consuming clinical trials. The present invention further provides a method for the treatment or prophylaxis of a disease or condition in a subject by generating T-cells reactive to an antigenic molecule and administering an effective amount of antigen-reactive T-cells to the subject or other compatible host. Furthermore, the present invention permits the generation of dendritic cell/T-cell populations for use in cellular immunotherapy. | 2009-04-16 |
20090098091 | Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis - The present disclosure teaches analogs of human chemokines and methods of using them in the prevention, treatment, and ameliorization of diseases that can benefit from therapeutic angiogenesis. The teachings are generally directed to compositions comprising SDF-1 mimetics, as well as methods that include the use of SDF-1 mimetics to induce neo-vessel formation. The disclosure also teaches articles of manufacture that can be useful in practicing the methods taught herein. | 2009-04-16 |
20090098092 | Composite Bone Material and Method of Making and Using Same - Bone composite implants and the method of constructing bone composite implants are disclosed which may be used in the repair, replacement, and/or augmentation of various portions of animal or human skeletal systems. Furthermore, the bone composite implants of the present invention may be considered load-bearing implants which are incorporated into the skeletal structure of the patient. | 2009-04-16 |
20090098093 | GENERATION OF INNER EAR CELLS - Methods for generating cells of the inner ear, e.g., hair cells and supporting cells, from stem cells, e.g., mesenchymal stem cells, are provided, as well as compositions including the inner ear cells. Methods for the therapeutic use of the inner ear cells for the treatment of hearing loss are also described. | 2009-04-16 |
20090098094 | SKELETAL MUSCLE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to novel uses of muscle-derived progenitor cells for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the novel use of MDCs for the increase of skeletal muscle mass in athletes or other organisms in need of greater than average skeletal muscle mass. | 2009-04-16 |
20090098095 | METHOD OF EXPANDING DOUBLE NEGATIVE T CELLS - A method of expanding double negative T cells in culture is described. The method comprises (a) providing a starting sample comprising DN T cells or precursors thereof; (b) substantially depleting CD8 | 2009-04-16 |
20090098096 | AGENT FOR CORRECTING STRESS-INDUCING NEURO-MEDIATOR, NEURO-ENDOCRINE AND METABOLIC DISTURBANCES AND METHOD FOR PREVENTING AND TREATING CONCOMITANT PATHOLOGICAL CONDITIONS - The invention relates to medicine, in particular to pharmacology, and is embodied in the form of an agent for limiting neuro-mediator, neuro-endocrine and metabolic disturbances generating the disorders of a central nervous system and functional somatic disorders. The inventive agent is based on a DSIP (delta sleep inducing peptide) or a derivative chemically related thereto and can be used for correcting and preventing functional shifts in a central nervous system and concomitant somatic disorders caused by unfavourable and extreme environmental factors and different pathological conditions of an organism or during the ageing thereof. The inventive method for preventing and treating stress states with the aid of the inventive agent is characterised in that the inventive compositions can be administrated: intranasally in the form of intranasal drops or spray; sublingually in the form of resorbable tablets and capsules; in the form of powders, suppositories, ointments and creams; in the form of different injections (intracutaneous, hypodermic, intramuscular, and intravenous); in the form of different cosmetic agents (creams, lotions, tonics, cosmetic milk, foam, soap, etc.) and in the form of infant food components. | 2009-04-16 |
20090098097 | COMPOSITION FOR NORMALIZING BLOOD PRESSURE - The present invention aims to provide a composition suitable for normalizing the blood pressure, which is useful as food, health food, supplement, nutritional supplement, food for specified health uses, food with nutrient function claims, pharmaceutical product, quasi-drug, feed or pet food. | 2009-04-16 |
20090098098 | ANTI-BACTERIAL, ANTI-VIRUS, AND ANTI-FUNGUS COMPOSITION, ITS PREPARATION AND USE - The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) a mixture of a coenzyme having reducing ability and quinones, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard. Additionally, the present composition can be applied to human being such as applying to hand, foot, genital organs, oral cavity, and the like in a lower dose to attain the effect of destroying of bacteria, viruses, and fungi. | 2009-04-16 |
20090098099 | PLANT TRANSFORMED WITH POLYNUCLEOTIDE ENCODING LEPIDOPTERAN-ACTIVE BACILLUS THURINGIENSIS DELTA-ENDOTOXIN - Disclosed are | 2009-04-16 |
20090098100 | Hormonally up-regulated, neu-tumor-associated kinase - This invention relates generally to a novel serine/threonine protein kinase, specifically to hormonally up-regulated, neu-tumor-associated kinase (HUNK); and to the nucleotide sequence encoding it. The kinase is temporally expressed during postnatal mammary development in a spatially heterogeneous manner in certain subsets of cells, and overexpressed in a subset of primary breast cancers. The invention further relates to an analysis of a correlation between carcinogenesis and postnatal development, particularly mammary development, especially associated with parity; to methods of using the kinase, or gene encoding it, as markers, prognostic tools, screening tools and therapies, in vitro and in vivo, that are based upon that correlation; and to the regulation of pregnancy-induced changes in the mammary tissue that occur in response to estrogen and progesterone. | 2009-04-16 |
20090098101 | COMPOSITIONS AND METHODS FOR RIBONUCLEASE-BASED THERAPEUTICS - The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer). | 2009-04-16 |
20090098102 | Cosmetic Composition Containing Enzyme and Amino Acid - The present invention relates to a skin cosmetic composition containing enzyme and amino acid. More particularly, the skin cosmetic composition according to the invention contains enzyme and amino acid, and thus safely improves stratum corneum thickening resulting from the progression of skin aging, improves skin drying occurring during keratin removal, and shows excellent skin moisturizing and whitening effects. | 2009-04-16 |
20090098103 | Modified factor VII polypeptides and uses thereof - Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 2009-04-16 |
20090098104 | Method for Diagnosing Cardiovascular Diseases - Method for diagnosing a cardiovascular disease in an individual comprising the steps of: providing a sample of an individual; determining the amount of cytokeratin-18 (CK-18) or fragments thereof and/or interleukin-1β precursor (IL-1β precursor) in said sample; comparing the amount of CK-18 or fragments thereof and/or IL-1β precursor in said sample to the amount of CK-18 or fragments thereof and/or IL-1β precursor present in a reference control of at least one individual not suffering from a cardiovascular disease; and diagnosing a cardiovascular disease if the amount of CK-18 or fragments thereof in the sample is increased in comparison to the amount of CK-18 or fragments thereof in the reference control and/or the amount of IL-1β precursor in the sample is decreased in comparison to the amount of IL-1β precursor in the reference control. | 2009-04-16 |
20090098105 | Treatment of neurodegenerative diseases by the use of scd4 inhibitors - The present invention relates to the use of SCD4 interacting molecules, especially SCD4 inhibitors, for the preparation of a medicament for the treatment of neurodegenerative diseases, particularly Alzheimer's disease. | 2009-04-16 |
20090098106 | PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-kB ACTIVITY - A method of treating a disease associated with NF-κB activity. The method is effected by providing to a subject in need thereof a therapeutically effective amount of an agent capable of modulating NIK-HC8 binding. | 2009-04-16 |
20090098107 | Method of Detecting Relative Risk for the Onset of Atopic Dermatitis by Gene Single Nucleotide Polymorphism Analysis - The present invention provides a method of discriminating a relative risk for the morbidity of atopic dermatitis of a test subject comprising: analyzing gene polymorphism of two or more of genes related to onset of atopic dermatitis using a sample isolated from a statistically significant number of normal persons and patients of atopic dermatitis to determine relative ratios (percentages (%)) related to the individual gene polymorphism of individual derived from the analysis; and calculating an odds ratio according to specified gene polymorphism from the relative ratio; and using, as a discrimination criterion, a combination of two or more of gene polymorphisms showing a synergetically higher odds ratio than odds ratios according to individual gene polymorphism. The method is useful for predicting susceptibility of an AD patient to chemicals based on genes and for selecting the diagnostic and/or therapeutic agent by eliminating harmful drug reactions from the analysis of principal factors related to onset and development of AD and interaction among these genes, and for determining a diagnostic method and therapeutic method using the detection method of morbidity risk. | 2009-04-16 |
20090098108 | USE OF LONG-ACTING GLP-1 RECEPTOR AGONISTS TO IMPROVE INSULIN SENSITIVITY AND LIPID PROFILES - The present invention provides to at least one novel human GLP-1 receptor agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 receptor agonist, or specified portion or variant, GLP-1 receptor agonist, or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including the use of long acting GLP-1 receptor agonists to improve insulin sensitivity or lipid profiles in obesity and related therapeutic and/or diagnostic compositions, methods and devices. | 2009-04-16 |
20090098109 | Compositions and Methods For Enhancing Neuronal Plasticity and Regeneration - The present invention relates PirB expression and function in nervous tissue. PirB expressed in neurons acts to restrict plasticity of neural circuits, and/or, restrict competition between circuits with different activity patterns or levels, for cortical representation. Thus, the present invention relates to methods of increasing nervous system plasticity and associated disorders and diseases in a subject comprising administering to the subject an agent which modulates the activity, signal transduction or expression of PirB in neurons of the subject. | 2009-04-16 |
20090098110 | INJECTABLE FORMS OF SOLID-FORMING CROSSLINKED BIOELASTIC BIOPOLYMERS FOR LOCAL DRUG DELIVERY - A method for delivering a compound of interest to a selected region in a subject is carried out by administering a composition to the region of interest, the composition comprising a cross-linked bioelastomer in combination with the compound of interest non-covalently combined with the cross-linked bioelastomer. In some embodiments, the composition is produced by the process of cross-linking a bioelastomer to produce a cross-linked polymer thereof, and then combining said cross-linked polymer with said compound of interest. Methods of making the compositions, and kits useful for carrying out the method, are also described. | 2009-04-16 |
20090098111 | Methods for modulating checkpoint activation through TopBP1 - ATR kinase is a key regulator of checkpoint responses to incompletely replicated and damaged DNA. Without this checkpoint, cells will enter mitosis prematurely, likely resulting in cell death. The invention provides methods and reagents to either block or activate the activation of the ATR kinase checkpoint, through, for example, either blocking or activating the expression of an ATR activator TopBP1. The invention also provides screening methods to identify additional ToBP1 inhibitors or activators that may be used to modulate the activity of the ATR checkpoint. | 2009-04-16 |
20090098112 | NOVEL ANTIBODIES - The present invention relates to the use of VEGF antagonists and a novel anti-α5β1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-α5β1 antibodies and methods of making and using them. | 2009-04-16 |
20090098113 | Activin-ActRIIa antagonists and uses for promoting bone growth - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 2009-04-16 |
20090098114 | ALK7 and myostatin inhibitors and uses thereof - The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass. | 2009-04-16 |
20090098115 | Cell lines and animal models of HER2 expressing tumors - The present invention concerns cell lines and animal models of HER2-expressing tumors. In particular, the invention concerns cell lines and animal models of HER2-expressing tumors not responding or responding poorly to treatment with trastuzumab (HERCEPTIN®, Genentech, Inc.). The animal models and cell lines of the invention are useful for evaluating the efficacy of various therapeutic approaches for the treatment of such tumors. | 2009-04-16 |
20090098116 | IMMUNOGENIC COMPOSITIONS FOR INDUCTION OF ANTI-TUMOR IMMUNITY - The invention relates to the use of an immunogen selected from the group consisting of | 2009-04-16 |
20090098117 | COMPOSITION COMPRISING AND METHOD OF USING ANGIOPOIETIN-LIKE PROTEIN 3 ANGPTL3 - The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angptl3 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention. | 2009-04-16 |
20090098118 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. | 2009-04-16 |
20090098119 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. | 2009-04-16 |
20090098120 | Compositions and methods for the treatment of immune related diseases - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 2009-04-16 |
20090098121 | Immunoglobulin Directed Biocides - The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense. | 2009-04-16 |
20090098122 | sRAGE Mimetibody, Compositions, Methods and Uses - Mammalian sRAGE mimetibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to reduce or inhibit the binding of RAGE and its ligands and to treat RAGE-related diseases are also disclosed. | 2009-04-16 |
20090098123 | HCV CORECEPTOR AND METHODS OF USE THEREOF - The invention relates to the discovery that the Claudin-1 protein functions as a co-receptor for entry of HCV into cells. Methods of inhibiting, preventing or mitigating HCV infections by inhibiting HCV interactions with Claudin-1 are provided. Methods of identifying agents or compounds that interfere with HCV interactions with Claudin-1 are also provided. Finally, useful kits, cell culture compositions, agents, and compounds related to the inhibition of HCV interactions with Claudin-1 are also disclosed. | 2009-04-16 |